Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people. Abbott’s vascular division has an industry-leading pipeline and a comprehensive portfolio of market-leading products for cardiac and vascular care, including products for coronary artery disease, vessel closure, endovascular disease and structural heart disease.
Clonmel has been part of a global network of Abbott vascular manufacturing sites since 1998. AVD’s vision is “to improve the lives of patients and their families around the world through our passionate commitment to innovation in cardiac & vascular science.” This is driven by our five divisional strategic themes, which cascade through to everyone.
At our site, all activity is shaped by these themes, ensuring full strategic alignment, where the belief exists that our success is twinned with our unstinting commitment to operational excellence. Within this, our site is both positioned and recognised as the divisional “Centre of Excellence” for Stent and Drug Eluting Stent manufacturing.
The site has more than 1,000 employees primarily dedicated to manufacturing but also includes process development. The facility, which is more than 250,000 square feet sits on 19 acres and has three distinct areas manufacturing products for the treatment of coronary and endovascular diseases, namely:
Abbott Vascular is the world's leader in drug eluting stents. Abbott Vascular provides our customers with products such as XIENCE V®, XIENCE Prime® and XIENCE XpeditionTM drug eluting stent systems. We also manufacture their predecessor bare-metal stent products (non-drug coated). Both products include the stent (drug coated or bare) and a catheter delivery system needed to place the stents during a patient’s angioplasty procedure. Both of these sub-assemblies are also manufactured at the site. As a result of the site’s excellent performance, Clonmel now provides 100% of both Abbott’s stents and DES devices. Due to the nature of our products, quality is paramount. Our quality system has ensured we put our patients first while achieving dramatic continuous improvement in the site’s performance, with double-digit improvement in our non-conformance rate and double-digit reductions in cost.
We hope this overview gives you some insight into our site. Our products help improve people’s lives. We are the flagship manufacturing facility in Abbott Vascular, and high-performance is expected to ensure product quality. It is our passport to sell products around the world and is a key component of our market-leading position.
Michael Tarrant, Manager, Business Excellence | Phone: +353-52-6173456 | Email: email@example.com